|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Tarix Pharmaceuticals LTD
| | | Phone: | (617) 827-6824 | Year Established: | 2007 | Main Contact: | Richard Franklin, President & CEO | | Other Contacts: | John Benson, Finance Director Elizabeth Wagner, MS, MBA, VP, Corporate Development Joerg Gruber, Chairman
| | Company Description | Tarix Orphan is a private biopharmaceutical company that is developing TXA127 for rare neuromuscular and connective tissue diseases. TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 has been effective in animal models of Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy MDC1A, Marfan syndrome, and Dystrophic Epidermolysis Bullosa (DEB). Tarix Orphan has broad IP protection for TXA127 and Orphan Drug Designations (ODDs) have been granted for DMD LGMD and DEB in the U.S., and for DMD in Europe. Tarix Orphan aims to initiate a clinical trials for both DMD and DEB in early 2018 and has an active IND for a Phase II trial in DMD, as well as Fast Track designation for DMD.
The Company’s lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a multi-center Phase II clinical trial in peripheral blood stem cell transplantation, where it is being evaluated for its ability to enhance engraftment of platelets and white blood cells. TXA127 is also in two single center clinical trials at M D Anderson, one in cord blood transplantation and the other in myelodysplastic syndrome. In addition, TXA127 is being developed, under grants from the US government, as a treatment for radiation exposure.
Tarix’s second product, PanCyte, is a synthetic, long-acting cyclic analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on its use to treat serious pulmonary diseases. | |
|
|
|
|
|